JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic value of immune biomarkers in melanoma loco-regional metastases

  • 0Department of Clinical Medicine, Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway.
Plos One +

|

January 30, 2025

|

January 30, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Low FOXP3 tumor-infiltrating lymphocytes (TILs) and negative PD-L1 expression in melanoma lymph node metastases are linked to poorer survival. This study highlights their prognostic value in predicting patient outcomes.

Area Of Science

  • Oncology
  • Immunology
  • Pathology

Background

  • Prognosis for melanoma with loco-regional metastases is highly variable.
  • Adjuvant PD-L1 inhibitors improve outcomes, but the prognostic role of tumor PD-L1 expression and tumor-infiltrating lymphocytes (TILs) remains unclear.

Purpose Of The Study

  • To investigate the prognostic impact of tumor PD-L1 expression and counts of CD3, CD8, FOXP3, and PD-L1 TILs on survival in melanoma loco-regional metastases.

Main Methods

  • Immunohistochemistry was used to determine PD-L1 expression in tumor cells and TIL counts (CD3, CD8, FOXP3, PD-L1) in a series of 67 melanoma lymph node metastases using tissue microarrays.
  • Statistical analysis was performed to correlate these markers with patient survival.

Main Results

  • Low FOXP3 TIL count and negative tumor PD-L1 expression ( < 1%) were significantly associated with reduced survival in lymph node metastases.
  • Low FOXP3 TIL count correlated with lower CD8, CD3, and PD-L1 TIL counts.
  • Negative tumor PD-L1 expression was associated with lower CD8 and PD-L1 TIL counts, larger tumor size, and necrosis in lymph node metastases.

Conclusions

  • Low FOXP3 TIL count has a negative prognostic value in melanoma lymph node metastases.
  • Negative tumor PD-L1 expression also confirms a negative prognostic value in melanoma lymph node metastases.